Eloxx Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
Dosed first two patients in global Phase 2b EXACT study of exaluren in nonsense mutation Alport synd
Dosed first two patients in global Phase 2b EXACT study of exaluren in nonsense mutation Alport synd